Table 1 Clinical and laboratory characteristics of COVID-19 patients
From: Gasdermin-D activation by SARS-CoV-2 triggers NET and mediate COVID-19 immunopathology
Severity | Moderate | Severe | P value |
|---|---|---|---|
Demographics and clinical characteristics of COVID-19 patients | |||
 Number | 18 | 45 |  |
 Age | 63.29 ± 16.58 | 58.62 ± 16.85 | ns |
 Female | 10 (55.55%) | 22 (48.88%) | ns |
Respiratory status | |||
 Mechanical ventilation | 0 | 45 (100%) |  |
 Nasal-cannula oxygenΩ | 18 (100%) | 0 |  |
 Room air | 0 | 0 |  |
Outcome | |||
 Secondary infection | 0 | 12 (26.66%) | 0.013 |
 Deaths | 6 (33.33%) | 13 (28.88%) | ns |
Clinical—Comorbidities | |||
 Diabetes mellitus | 6 (33.33%) | 6 (13.33%) | ns |
 Cardiopathy | 3 (16.66%) | 5 (11.11%) | ns |
 Nephropathy | 1 (5.55%) | 7 (15.55% | ns |
 Pneumopathy | 4 (22.22%) | 6 (13.33%) | ns |
 Autoimmune diseases | 1 (5.55%) | 2 (4.44%) | ns |
 Cancer | 2 (11.11%) | 2 (4.44%) | ns |
 Stroke | 2 (11.11%) | 1 (2.22%) | ns |
 Obesity | 5 (27.77%) | 21 (48.88%) | ns |
 Arterial hypertension | 9 (50.0%) | 23 (51.11%) | ns |
 Immunodeficiency | 2 (11.11%) | 3 (6.66%) | ns |
 Smoking | 5 (27.77%) | 9 (20.0%) | ns |
Laboratorial Findings | |||
 CRP (mg/dL)* | 9.90 ± 6.18 | 12.21 ± 10.13 | ns |
 D-Dimers (μg/mL)** | 1.48 ± 1.61 | 3.30 ± 3.55 | 0.007 |
 LDH (U/L)# | 428.89 ± 205.23 | 746.60 ± 429.50 | 0.002 |
 Ferritin (ηg/mL)& | 911.01 ± 712.94 | 1109.47 ± 1547.36 | ns |
 Neutrophils × 103/μL | 6.0 ± 4.2 | 7.5 ± 3.6 | 0.02 |
 Lymphocytes × 103/μL | 1.4 ± 0.8 | 1.9 ± 1.5 | ns |
 Neutrophil/lymphocytes ratio¥ | 4.2 ± 5.25 | 3.9 ± 2.4 | ns |
 Platelets × 103/μL | 242.7 ± 103.8 | 287.3 ± 121.1 | ns |